ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

GLSI vs LYEL // FREE CASH FLOW YIELD

Greenwich LifeSciences Inc. (NASDAQ) VS. Lyell Immunopharma Inc. (NASDAQ) • 15-METRIC TALLY: GLSI 1 — LYEL 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GLSI VS. LYEL) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC GLSI LYEL SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -3.55% — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -41.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 LYEL /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.0 61.4 -8.36 LYEL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $278.9M $277.0M $1.9M GLSI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR GLSI REV LYEL REV GLSI GROSS % LYEL GROSS % GLSI FCF LYEL FCF
FY 2025 $0 $36.0K — — -$9.9M -$150.8M
FY 2024 $0 $61.0K — — -$7.3M -$162.9M
FY 2023 $0 $130.0K — — -$6.5M -$163.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GLSI // BETA —
LYEL // BETA —